Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LM-364 |
| Synonyms | |
| Therapy Description |
LM-364 is an antibody-drug conjugate (ADC) comprising an ANP-dependent antibody targeting NECTIN4 linked to a topoisomerase I inhibitor, which potentially inhibits growth of Nectin4-expressing tumors (Cancer Res (2026) 86 (7_Supplement): 4433). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LM-364 | LM364|LM 364 | NECTIN4 Antibody 14 | LM-364 is an antibody-drug conjugate (ADC) comprising an ANP-dependent antibody targeting NECTIN4 linked to a topoisomerase I inhibitor, which potentially inhibits growth of Nectin4-expressing tumors (Cancer Res (2026) 86 (7_Supplement): 4433). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07694765 | Phase Ib/II | LM-364 + Tislelizumab LM-364 | A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors | Not yet recruiting | AUS | 0 |